- Rezafungin has fast track and Qualified Infectious Disease Product (QIDP) designations to rezafungin for for the prevention of invasive fungal infections in adults undergoing allogeneic bone... read more
CytoSen Therapeutics, a private biopharmaceutical company accelerating innovation in Natural Killer (NK) cell therapy, announced on 9/27/18 it has received a favorable response from the U.S. Food... read more
Veracyte, Inc. (NASDAQ: VCYT)... read more
Proscia announced on 9/26/18 that it has closed an $8.3 million round of Series A financing from a group of East and West Coast venture capital firms. The funding was led by Boston-based Flybridge... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,